rss
Br J Ophthalmol 2004;88:1295-1298 doi:10.1136/bjo.2004.043232
  • Clinical science
    • Extended reports

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

  1. T Hamacher1,
  2. M Schinzel2,
  3. A Schölzel-Klatt3,
  4. H-M Neff4,
  5. H Maier5,
  6. G Schlaffer6,
  7. E Beausencourt7,
  8. M Jütte8,
  9. R Scholz9,
  10. C Lorger10,
  11. W C Stewart11,12
  1. 1Starnberg, Germany
  2. 2Hildesheim, Germany
  3. 3Berlin, Germany
  4. 4Marbach, Germany
  5. 5Gerolzhofen, Germany
  6. 6Neustadt, Germany
  7. 7Berchtesgaden, Germany
  8. 8Jena, Germany
  9. 9Biedenkopf, Germany
  10. 10Donauwörth, Germany
  11. 11Pharmaceutical Research Network, LLC, Charleston, SC, USA
  12. 12Carolina Eye Institute at the University of South Carolina School of Medicine, Columbia, SC, USA
  1. Correspondence to: W C Stewart MD Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412–2464, USA; infoprnorb.com
  • Accepted 21 March 2004

Abstract

Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC).

Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months.

Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p<0.001) compared to previous monotherapies including latanoprost, timolol, α agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a β blocker added to either CAI, α agonist, or pilocarpine, or CAI added to an α agonist, or latanoprost added to either CAI, α agonist, or β blocker (unfixed combination), and travoprost added to timolol (p<0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (−0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%).

Conclusion: In a clinical setting, patients who have their monotherapy or adjunctive therapy substituted with LTFC may experience reduced IOP, good tolerability, and continuation of therapy for the first 2–3 months of treatment.

Footnotes

  • This study was sponsored by Pfizer GmbH, Erlangen, Germany.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.